An outbreak of 2019‐nCoV infection has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID‐2019. In addition to the recommended antiviral drugs, such as interferon‐ɑ, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA‐dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug–drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID‐2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available.

中文翻译：

---

Favipiravir：关于2019-nCoV感染的临床试验的药代动力学和关注点。

2019年nCoV感染的爆发已遍布全球。没有特定的抗病毒药物被批准用于治疗COVID-2019。除了推荐的抗病毒药物（如干扰素ɑ，洛匹那韦/利托那韦，利巴韦林和磷酸氯喹）外，一些针对病毒RNA依赖性RNA聚合酶（RdRp）抑制剂的临床试验已经注册并启动。Favipiravir是一种嘌呤核酸类似物和有效的RdRp抑制剂，已批准用于流感，并已在多项临床试验中考虑使用。在这里，我们从药物代谢的角度总结了非那吡韦的药代动力学特征以及可能的药物相互作用。我们希望这将有助于法维拉韦在COVID-2019中的临床试验设计，作为有关体外的数据 尚无临床前动物研究中对病毒的抑制和功效。